Recent Research Analysts’ Ratings Changes for Janux Therapeutics (JANX)

A number of firms have modified their ratings and price targets on shares of Janux Therapeutics (NASDAQ: JANX) recently:

• 12/2/2025 – Janux Therapeutics had its “buy” rating reaffirmed by analysts at UBS Group AG. They now have a $57.00 price target on the stock.
• 12/2/2025 – Janux Therapeutics had its price target lowered by analysts at Stifel Nicolaus from $46.00 to $38.00. They now have a “buy” rating on the stock.
• 12/2/2025 – Janux Therapeutics had its price target lowered by analysts at HC Wainwright from $70.00 to $45.00. They now have a “buy” rating on the stock.
• 12/2/2025 – Janux Therapeutics had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $45.00 price target on the stock, down previously from $76.00.
• 12/2/2025 – Janux Therapeutics had its price target lowered by analysts at Bank of America Corporation from $58.00 to $49.00. They now have a “buy” rating on the stock.
• 12/2/2025 – Janux Therapeutics had its price target lowered by analysts at Cantor Fitzgerald from $200.00 to $150.00. They now have an “overweight” rating on the stock.
• 11/25/2025 – Janux Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $70.00 price target on the stock.
• 11/18/2025 – Janux Therapeutics is now covered by analysts at Wolfe Research. They set a “peer perform” rating on the stock.
• 11/8/2025 – Janux Therapeutics was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating.
• 11/7/2025 – Janux Therapeutics had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $76.00 price target on the stock.
• 11/7/2025 – Janux Therapeutics had its price target raised by analysts at Barclays PLC from $47.00 to $48.00. They now have an “overweight” rating on the stock.

Insiders Place Their Bets

In other Janux Therapeutics news, insider Andrew Hollman Meyer sold 16,665 shares of the business’s stock in a transaction dated Tuesday, October 28th. The shares were sold at an average price of $30.06, for a total transaction of $500,949.90. Following the sale, the insider directly owned 82,139 shares of the company’s stock, valued at $2,469,098.34. The trade was a 16.87% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Insiders have sold a total of 23,331 shares of company stock valued at $710,862 over the last ninety days. 29.40% of the stock is currently owned by company insiders.

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.